RS52941B - Kombinacija alfa 7 nikotinskih agonista i antipsihotika - Google Patents

Kombinacija alfa 7 nikotinskih agonista i antipsihotika

Info

Publication number
RS52941B
RS52941B RS20130387A RSP20130387A RS52941B RS 52941 B RS52941 B RS 52941B RS 20130387 A RS20130387 A RS 20130387A RS P20130387 A RSP20130387 A RS P20130387A RS 52941 B RS52941 B RS 52941B
Authority
RS
Serbia
Prior art keywords
mice
antipsychotic
schizophrenia
disorder
nicotinic
Prior art date
Application number
RS20130387A
Other languages
English (en)
Serbian (sr)
Inventor
Merouane Bencherif
Gregory J. Gatto
Kristen G. Jordan
Terry Hauser
Sharon R. Letchworth
Original Assignee
Targacept Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc. filed Critical Targacept Inc.
Publication of RS52941B publication Critical patent/RS52941B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
RS20130387A 2008-02-13 2009-02-13 Kombinacija alfa 7 nikotinskih agonista i antipsihotika RS52941B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2828208P 2008-02-13 2008-02-13
PCT/US2009/034062 WO2009102962A2 (en) 2008-02-13 2009-02-13 Combination of alpha 7 nicotinic agonists and antipsychotics

Publications (1)

Publication Number Publication Date
RS52941B true RS52941B (sr) 2014-02-28

Family

ID=40902222

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20130387A RS52941B (sr) 2008-02-13 2009-02-13 Kombinacija alfa 7 nikotinskih agonista i antipsihotika

Country Status (25)

Country Link
US (1) US20110059947A1 (enExample)
EP (2) EP2254598B1 (enExample)
JP (1) JP2011511845A (enExample)
KR (1) KR20100113163A (enExample)
CN (2) CN101977628A (enExample)
AU (1) AU2009214625A1 (enExample)
BR (1) BRPI0907570A2 (enExample)
CA (1) CA2715268A1 (enExample)
CO (1) CO6290706A2 (enExample)
CY (1) CY1114492T1 (enExample)
DK (1) DK2254598T3 (enExample)
EC (1) ECSP10010471A (enExample)
ES (1) ES2430622T3 (enExample)
HR (1) HRP20130749T1 (enExample)
IL (1) IL207389A0 (enExample)
MX (1) MX2010008875A (enExample)
NZ (1) NZ587312A (enExample)
PL (1) PL2254598T3 (enExample)
PT (1) PT2254598E (enExample)
RS (1) RS52941B (enExample)
RU (1) RU2481123C2 (enExample)
SG (1) SG188144A1 (enExample)
SI (1) SI2254598T1 (enExample)
WO (1) WO2009102962A2 (enExample)
ZA (1) ZA201005999B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
EP2619205B1 (en) 2010-09-23 2017-05-17 AbbVie Bahamas Ltd. Monohydrate of an azaadamantane derivative
EP2665478A1 (en) * 2011-01-18 2013-11-27 Targacept, Inc. Treatment of cognitive dysfunction in schizophrenia
US9139576B2 (en) 2011-05-03 2015-09-22 Merck Sharp & Dohme Corp. Aminomethyl biaryl benzotriazole derivatives
MX2015004285A (es) * 2012-10-02 2015-08-06 Sumitomo Dainippon Pharma Co Ltd Derivado de imidazol.
JP6807094B2 (ja) * 2016-04-29 2021-01-06 国立大学法人秋田大学 クロザピン又はその誘導体の血中薬剤濃度上昇リスク判定方法及び薬剤投与量判定方法
CN110087641B (zh) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
CN108727416B (zh) * 2017-04-20 2021-03-09 北京大学 三环杂芳香体系酰胺衍生物及其制备和用途
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
CN118806732A (zh) 2018-06-20 2024-10-22 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
BR112020026099A2 (pt) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico que contém asenapina
WO2022150560A1 (en) * 2021-01-08 2022-07-14 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
JP2024502474A (ja) 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための、尿素を有するヘテロ二環式化合物または類似体およびその組成物
DE102022114269A1 (de) 2022-06-07 2023-12-07 Rational Aktiengesellschaft Gargerät mit einem Selbstreinigungssystem sowie ein Verfahren zum Ändern von Reinigungsparametern für das Gargerät

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5712270A (en) 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
AU765142B2 (en) 1998-06-01 2003-09-11 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
BR0016168A (pt) * 1999-12-10 2002-08-20 Combinações terapêuticas de (s)-2-(benzilaminometil)-2,3,8,9tetrahidro-7h-1,4-dioxi no[2,3 -e]indol-8-ona e neurolépticos para o tratamento ou prevenção de distúrbios psicóticos
AU2001266100B9 (en) * 2000-06-27 2005-10-06 Laboratorios S.A.L.V.A.T., S.A. Carbamates derived from arylalkylamines
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6492386B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
AU2001282874A1 (en) 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
WO2002015662A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
JP2004506734A (ja) 2000-08-21 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用のキヌクリド置換ヘテロアリール部分
US6554086B1 (en) * 2000-10-27 2003-04-29 Invacare Corporation Obstacle traversing wheelchair
EP1345937B1 (en) 2000-12-22 2005-09-28 Almirall Prodesfarma AG Quinuclidine carbamate derivatives and their use as m3 antagonists
CA2476624A1 (en) * 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
JP2006510664A (ja) * 2002-12-06 2006-03-30 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー １−アザビシクロ［２．２．２］オクト置換フロ［２，３−ｃ］ピリジニルカルボキサミドの結晶性フマル酸塩及び該塩を含む組成物並びにその製造方法
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
WO2004099202A1 (en) * 2003-05-05 2004-11-18 Pharmacia & Upjohn Company Llc Quinuclidines substituted bentodioxine carboxamides for the treatment of neurodegenerative diseases
US7309699B2 (en) * 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives
EP1699488A2 (en) * 2003-12-23 2006-09-13 Pfizer Products Incorporated Therapeutic combination for cognition enhancement and psychotic disorders
EP1863485A2 (en) * 2005-03-18 2007-12-12 Abbott Laboratories Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions

Also Published As

Publication number Publication date
WO2009102962A2 (en) 2009-08-20
CN101977628A (zh) 2011-02-16
PL2254598T3 (pl) 2013-12-31
EP2254598B1 (en) 2013-07-10
JP2011511845A (ja) 2011-04-14
IL207389A0 (en) 2010-12-30
PT2254598E (pt) 2013-10-16
SG188144A1 (en) 2013-03-28
CO6290706A2 (es) 2011-06-20
ES2430622T3 (es) 2013-11-21
WO2009102962A3 (en) 2009-10-08
HRP20130749T1 (en) 2013-10-11
AU2009214625A1 (en) 2009-08-20
SI2254598T1 (sl) 2013-10-30
RU2010137787A (ru) 2012-03-20
EP2254598A2 (en) 2010-12-01
ZA201005999B (en) 2011-05-25
NZ587312A (en) 2011-12-22
KR20100113163A (ko) 2010-10-20
ECSP10010471A (es) 2010-10-30
MX2010008875A (es) 2010-08-31
DK2254598T3 (da) 2013-07-29
CA2715268A1 (en) 2009-08-20
BRPI0907570A2 (pt) 2019-09-24
CN103143023A (zh) 2013-06-12
HK1147954A1 (en) 2011-08-26
RU2481123C2 (ru) 2013-05-10
US20110059947A1 (en) 2011-03-10
EP2633868A1 (en) 2013-09-04
CY1114492T1 (el) 2016-10-05

Similar Documents

Publication Publication Date Title
EP2254598B1 (en) Combination of alpha 7 nicotinic agonists and antipsychotics
Wong et al. Relationships between mitochondrial dysfunction and neurotransmission failure in Alzheimer’s disease
Echeverria et al. Cotinine: a potential new therapeutic agent against Alzheimer's disease
Nguyen et al. Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AβPPL/S transgenic mice
US20100178277A1 (en) Methods and compositions for stimulating cells
WO2009135091A1 (en) Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
WO2008036410A2 (en) Methods and compositions for treating amyotrophic lateral sclerosis (als)
WO2022215080A1 (en) A combined use of ketamine and retigabine (ezogabine) for the treatment of psychiatric disorders
Zhang et al. Davunetide improves spatial learning and memory in Alzheimer's disease-associated rats
Chagraoui et al. 5-HT6 receptors: Contemporary views on their neurobiological and pharmacological relevance in neuropsychiatric disorders
Kim et al. Unacylated Ghrelin Protects Against Age‐Related Loss of Muscle Mass and Contractile Dysfunction in Skeletal Muscle
Perkins et al. Alternative utrophin mRNAs contribute to phenotypic differences between dystrophin‐deficient mice and Duchenne muscular dystrophy
Saba et al. Riluzole restores memory and brain energy metabolism in AβPP-PS1 mouse model of Alzheimer's disease
Tsai Semax, an analogue of adrenocorticotropin (4–10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome
CN100525764C (zh) 吡唑并吡啶在制备治疗认知缺陷的药物中的应用
Cacabelos Pharmacogenetics in Alzheimer’s disease drug discovery and personalized treatment
KR20240004214A (ko) 신경변성 질환의 치료 및 예방에 사용하기 위한 폴리펩티드
HK1147954B (en) Combination of alpha 7 nicotinic agonists and antipsychotics
HK1185794A (en) Combination of alpha 7 nicotinic agonists and antipsychotics
Haynes The effects of fluphenazine on the neuromuscular phenotype in a mouse model of spinal muscular atrophy
WO2023280550A1 (en) Sco-spondin-derived polypeptides for enhancing synaptic transmission
Cassidy et al. Physiotherapy management of the ataxias towards best clinical practice: 2016 guideline update
Barrett et al. The European Histamine Research Society 48th Annual Meeting, May 15–18th, 2019 Krakow, Poland
Spaulding Towards a Unifified Disease Mechanism for tRNA Synthetase-Mediated Peripheral Neuropathy
Dowling et al. Investigating feasibility of use of an Android Smart Phone Application (MoveIt) as a clinical outcome measure